

Antiandrogen Therapies for non-metastatic Castration-Resistant Prostate Cancer: Effectiveness and Value

Key Stakeholder Organizations

ICER has identified the following organizations as key stakeholders for its upcoming report on treatments for non-metastatic Castration-Resistant Prostate Cancer. ICER will invite input from the following organizations, and welcomes suggestions from the broader community on additional organizations to add to this list. ICER often receives comments from individual patients and clinicians, and invites the public to submit recommendations for key stakeholders in these categories.

For a complete list of key dates and opportunities for input on this project, please visit [ICER's website](#).

- American Cancer Society
- American Society for Clinical Oncology
- Astellas
- Janssen
- Pfizer
- Prostate Advocates Aiding Choices in Treatment (PAACT Inc)
- Prostate Conditions Education Council
- National Alliance of State Prostate Cancer Coalitions
- Prostate Cancer International
- National Cancer Institute
- Us TOO International Prostate Cancer Education & Support
- Prostate Health Education Network
- Men's Health Network
- Malecare
- Prostate Cancer Research Institute
- Prostate Cancer Foundation
- Zero Cancer – End of Prostate Cancer